Trade

with

Celgene Corp
(NASDAQ: CELG)
AdChoices
92.00
+3.88
+4.40%
After Hours :
92.30
+0.30
+0.33%

Open

88.65

Previous Close

88.12

Volume (Avg)

7.98M (4.38M)

Day's Range

88.57-92.55

52Wk Range

66.85-96.50

Market Cap.

73.55B

Dividend Rate ( Yield )

-

Beta

1.10

Shares Outstanding

799.51M

P/E Ratio (EPS)

53.19 (1.73)

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Biotechnology
Highlights
Analyst Recommendation: Outperform
    • Revenue

    • 6.49B

    • Net Income

    • 1.45B

    • Market Cap.

    • 73.55B

    • Enterprise Value

    • -

    • Net Profit Margin %

    • 20.82

    • PEG (Price/Earnings Growth) Ratio

    • 0.74

    • Beta

    • 1.10

    • Forward P/E

    • 17.70

    • Price/Sales

    • 11.10

    • Price/Book Value

    • 15.15

    • Price/Cash flow

    • 35.21

      • EBITDA

      • 2.13B

      • Return on Capital %

      • 10.62

      • Return on Equity %

      • 28.55

      • Return on Assets %

      • 10.62

      • Book Value/Share

      • 6.07

      • Shares Outstanding

      • 799.51M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Outperform
        • 1 Year Price Target

        • 106.00

        • Credit Rating

        • A

        • Analysts

        • 8

        • EPS Estimate

        • 4.45

        • Cashflow Estimate

        • 5.32

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 17.10

          • 40.73

          • Net Income

            YTD/YTD (last year)

          • -0.40

          • 17.04

          • Net Income

            Q/Q (last year)

          • 25.00

          • 98.90

          • Sales (Revenue)

            5-Year Annual Average

          • 23.56

          • 63.43

          • Net Income

            5-Year Annual Average

          • -

          • 10.65

          • Dividends

            5-Year Annual Average

          • -

          • 15.81

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 94.82

            • 82.75

            • Pre-Tax Margin

            • 24.15

            • 39.38

            • Net Profit Margin

            • 20.82

            • 31.33

            • Average Gross Margin

              5-Year Annual Average

            • 92.80

            • 82.99

            • Average Pre-Tax Margin

              5-Year Annual Average

            • 29.90

            • 33.42

            • Average Net Profit Margin

              5-Year Annual Average

            • 25.80

            • 199.05B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • 1.39

              • 0.76

              • Current Ratio

              • 5.44

              • 2.92

              • Quick Ratio

              • 4.92

              • 2.35

              • Interest Coverage

              • 14.59

              • 38.02

              • Leverage Ratio

              • 3.22

              • 2.21

              • Book Value/Share

              • 6.07

              • 4.76

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • 52.63

                • 238.10

                • P/E Ratio 5-Year High

                • 55.92

                • 634.30

                • P/E Ratio 5-Year Low

                • 13.91

                • 124.82

                • Price/Sales Ratio

                • 10.98

                • 8.94

                • Price/Book Value

                • 14.99

                • 8.12

                • Price/Cash Flow Ratio

                • 35.21

                • 47.85

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • 28.55

                    (22.30)

                  • 37.63

                    (27.20)

                  • Return on Assets %

                    (5-Year Average)

                  • 10.62

                    (13.00)

                  • 17.22

                    (13.81)

                  • Return on Capital %

                    (5-Year Average)

                  • 15.11

                    (17.30)

                  • 21.78

                    (17.31)

                  • Income/Employee

                  • 287.14k

                  • 117.08k

                  • Inventory Turnover

                  • 1.11

                  • 1.48

                  • Asset Turnover

                  • 0.51

                  • 0.55

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  1.81B
                  Operating Margin
                  27.86
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  35.21
                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Biotechnology

                  Type

                  Aggressive Growth

                  Style

                  Large Growth

                  Celgene Corp is incorporated in Delaware. The Company is an integrated biopharmaceutical company engaged in the discovery, development and commercialization of new therapies designed to treat cancer and immune-inflammatory related di...moreseases. The Company is engaged in new research and development designed to bring new therapies to market and we are involved in research in several scientific areas that may deliver proprietary next-generation therapies, targeting areas including intracellular signaling pathways, protein homeostasis and epigenetics in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies. The Company’ commercial stage products include REVLIMID(r), VIDAZA(r), ABRAXANE(r), POMALYST(r)/IMNOVID(r), THALOMID(r) (inclusive of ...moreThalidomide CelgeneTM), ISTODAX(r) and azacitidine for injection (generic version of VIDAZA(r)). The Company faces competition from Amgen, AstraZeneca, Bristol-Myers-Squibb, Eisai, Gilead, Johnson & Johnson, Novartis, Pharmacyclics, Roche/Genentech, Sanofi and Takeda, AbbVie, Amgen, Biogen Idec, Eisai, Johnson & Johnson, Merck, Pfizer and UCB S.A. Regulation by governmental authorities in the United States and other countries is a significant factor in the manufacture and marketing of pharmaceuticals and in its ongoing research and development activities.lessless

                  Key People

                  Perry A. Karsen

                  CEO, Divisional/Executive VP

                  Robert J. Hugin

                  CEO/Chairman of the Board/Director

                  Peter N. Kellogg

                  Executive VP/CFO

                  Lawrence Stein

                  Executive VP/General Counsel/Secretary

                  Mr. Thomas O. Daniel

                  Executive VP/President, Divisional

                  • Celgene Corp

                  • 86 Morris Avenue

                  • Summit, NJ 07901

                  • USA.Map

                  • Phone: +1 908 673-9000

                  • Fax: +1 908 673-9001

                  • celgene.com

                  Incorporated

                  0

                  Employees

                  5,100